TP53 and B-cell chronic lymphocytic leukemia: As documented by the IC50 (50% inhibition concentration) values, in vitro treatment with DCA induced a significant and progressive reduction of cell viability, with respect to the untreated cultures assessed at the same time points (24 and 48 hours), in all the primary B-CLL patient cell cultures, irrespectively of the p53 status (Table 2).